Zobrazeno 1 - 10
of 70
pro vyhledávání: ''
Autor:
Werner Lichtenegger, Georg Heinrich, Inga Bekes, Julia Jückstock, Thomas W. P. Friedl, Robert E. Coleman, Matthias W. Beckmann, Volkmar Müller, Sara Y. Brucker, Ralf Lorenz, Sven Mahner, Wolfgang Janni, Hans Tesch, Andreas Schneeweiss, Tanja Fehm, Lothar Häberle, Helmut Forstbauer, Jens Uwe Blohmer, Visnja Fink, Peter A. Fasching, Jens Huober, Brigitte Rack
Publikováno v:
JAMA Oncol
Importance Bisphosphonate treatment in patients with early breast cancer has become part of care, but the optimal treatment duration is still unclear. Objective To compare 2 vs 5 years of zoledronate treatment following adjuvant chemotherapy in patie
Publikováno v:
JAMA Dermatol
IMPORTANCE: Although several single-center studies have estimated that granuloma annulare may account for approximately 0.1% to 0.4% of new patients presenting to dermatologists, large-scale population-based studies estimating the prevalence and inci
Autor:
Suma Choorapoikayil, Kai Zacharowski, Isabel Taeuber, Eva Herrmann, Patrick Meybohm, Leila Messroghli, Stephanie Weibel, Peter Kranke, Vanessa Neef, Tobias Schlesinger
Publikováno v:
JAMA Surg
Importance Tranexamic acid (TXA) is an efficient antifibrinolytic agent; however, concerns remain about the potential adverse effects, particularly vascular occlusive events, that may be associated with its use. Objective To examine the association b
Publikováno v:
JAMA Dermatol
Importance Topical calcineurin inhibitors (TCIs) are commonly used as second-line treatment for atopic dermatitis. In 2006, the US Food and Drug Administration issued a black box warning against TCI use, citing data from case reports and animal studi
Autor:
PharmD, Susamma M Wilson, Eduardo Bruera, Aline Rozman de Moraes, Zhanni Lu, Sriram Yennurajalingam, John M Najera, David Hui, Joseph Arthur, Tonya Edwards, Kristy Nguyen, Shirley Darlene Ethridge, Michal J Kubiak, Jimin Wu, Suresh K. Reddy, Yu Qian, Elif Erdogan, Saima Rashid, Manju P Joy, Leela Kuriakose, Jimi S Malik
Publikováno v:
JAMA Oncol
IMPORTANCE: One of the main aims of research on nonmedical opioid use (NMOU) is to reduce the frequency of NMOU behaviors through interventions such as universal screening, reduced opioid exposure, and more intense follow-up of patients with elevated
Autor:
N. Lynn Henry, Robert A. Bagramian, Mark M. Schubert, Amy K. Darke, Shaker R. Dakhil, Danika L. Lew, Catherine Van Poznak, James L. Wade, Dawn L. Hershman, Justin D. Floyd, Carol M. Moinpour, Michael J. Fisch, Joseph M. Unger, Lisa Hansen, Julie R. Gralow
Publikováno v:
JAMA Oncol
Importance Osteonecrosis of the jaw (ONJ) affects patients with cancer and metastatic bone disease (MBD) treated with bone-modifying agents (BMAs), yet the true incidence is unknown. Objective To define the cumulative incidence of ONJ at 3 years in p
Autor:
Kunle Odunsi, Peter J. Frederick, Emese Zsiros, Chong Wang, Kristopher Attwood, Shashikant Lele, Eduardo Cortes Gomez, Shanmuga Reddy Chilakapati, Sarah Lynam, Song Liu, S.N. Akers
Publikováno v:
JAMA Oncol
Importance Treatment options for recurrent ovarian cancer are of limited clinical benefit and adversely affect patient quality of life, representing an unmet need for tolerable effective therapies. Objective To assess the efficacy and safety of a com
Autor:
C. Dalban, Laurence Gladieff, Jalid Sehouli, Giorgia Mangili, Magali Provansal, Ugo De Giorgi, Isabelle Ray-Coquard, Hans Joachim Lück, Fabien Brocard, Andreas Schnelzer, Sandro Pignata, Keiichi Fujiwara, Annick Chevalier-Place, Philipp Harter, Patricia Pautier, Domenica Lorusso, Pierre Heudel, Ignace Vergote, Anne Floquet, Frédéric Selle
Publikováno v:
JAMA Oncol
Importance To our knowledge, this is the first randomized trial in sex cord-stromal tumors, and it establishes weekly paclitaxel as standard-of-care therapy after platinum-based therapy in this setting. Objective To determine the efficacy of weekly p
Autor:
Jake J. Lee, John S. Schneider, Dorina Kallogjeri, Jay F. Piccirillo, Murali M. Chakinala, Andrew M. Peterson
Publikováno v:
JAMA Otolaryngol Head Neck Surg
Importance Other than nasal moisturizers, no standard-of-care medical therapy exists for epistaxis in hereditary hemorrhagic telangiectasia (HHT). With epistaxis as the greatest cause of morbidity in patients with HHT, there is a need to identify eff
Publikováno v:
JAMA Dermatol
IMPORTANCE: Up to 90% of patients treated with an epidermal growth factor receptor inhibitor (EGFRi) experience cutaneous toxic effects that are negatively associated with quality of life and lead to treatment interruptions. The Skin Toxicity Evaluat